The PCSK9 gene R46L variant is associated with lower plasma lipid levels and cardiovascular risk in healthy U.K. men.
about
Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry studyScreening for familial hypercholesterolaemia in childhood: Avon Longitudinal Study of Parents and Children (ALSPAC)What is the impact of PCSK9 rs505151 and rs11591147 polymorphisms on serum lipids level and cardiovascular risk: a meta-analysisGenetic variation at the PCSK9 locus moderately lowers low-density lipoprotein cholesterol levels, but does not significantly lower vascular disease risk in an elderly populationEffects of PCSK9 genetic variants on plasma LDL cholesterol levels and risk of premature myocardial infarction in the Italian populationCorrelation of PCSK9 gene polymorphism with cerebral ischemic stroke in Xinjiang Han and Uygur populations.The proprotein convertase subtilisin/kexin type 9 gene E670G polymorphism and serum lipid levels in the Guangxi Bai Ku Yao and Han populationsPCSK9 is a critical regulator of the innate immune response and septic shock outcome.The Influence of OLR1 and PCSK9 Gene Polymorphisms on Ischemic Stroke: Evidence from a Meta-AnalysisThe associations between proprotein convertase subtilisin/kexin type 9 E670G polymorphism and the risk of coronary artery disease and serum lipid levels: a meta-analysis.Genetic variability within the cholesterol lowering pathway and the effectiveness of statins in reducing the risk of MIPlasma PCSK9 preferentially reduces liver LDL receptors in miceDifferential effects of PCSK9 loss of function variants on serum lipid and PCSK9 levels in Caucasian and African Canadian populations.The genetic spectrum of familial hypercholesterolemia in PakistanVariation in PCSK9, low LDL cholesterol, and risk of peripheral arterial disease.PCSK9: an emerging target for treatment of hypercholesterolemia.The role of proprotein convertase subtilisin/kexin type 9 in hyperlipidemia: focus on therapeutic implications.PCSK9 Loss-of-Function Variants, Low-Density Lipoprotein Cholesterol, and Risk of Coronary Heart Disease and Stroke: Data From 9 Studies of Blacks and Whites.The Proprotein Convertases in Hypercholesterolemia and Cardiovascular Diseases: Emphasis on Proprotein Convertase Subtilisin/Kexin 9.Effect of E670G Polymorphism in PCSK9 Gene on the Risk and Severity of Coronary Heart Disease and Ischemic Stroke in a Tunisian Cohort.PCSK9 is phosphorylated by a Golgi casein kinase-like kinase ex vivo and circulates as a phosphoprotein in humans.Proprotein convertase subtilisin/kexin type 9 gene E670G polymorphism interacts with alcohol consumption to modulate serum lipid levels.The PCSK9 gene E670G polymorphism affects low-density lipoprotein cholesterol levels but is not a risk factor for coronary artery disease in ethnic Chinese in Taiwan.Characterization of novel mutations in the catalytic domain of the PCSK9 gene.Large-Scale Phenome-Wide Association Study of Variants Demonstrates Protection Against Ischemic Stroke
P2860
Q24645376-B7D974F5-D04C-401C-AFB7-43199A05FCA6Q33630769-E68A3766-43D6-477F-86EC-2BCE855AAB6BQ33792275-51B7A049-3A67-4460-BFD7-9AB3C0949919Q33848024-AB920E79-B68C-433C-A973-9B0C8F61593AQ34188099-349B759A-E7D0-4466-AE2D-E603AF10F858Q34306545-1802A4AC-2E8C-4D8B-8C3D-F77D8C2F3F00Q34559768-1CB51E03-7C1C-4E7F-ACEC-B20D04EF5617Q35125516-B187CF77-ECA7-4216-ADBA-FF0D9823F243Q35868554-2612E2EF-7CAA-4079-A79B-7F8B52DD1E32Q36292659-3C741DED-A892-42BF-8EAF-3DE658EB056DQ36301394-9601B1FD-577F-465F-B097-42137812EF92Q36662650-E49D3219-E4E6-4590-BEB6-15C79A0BB0EFQ36866980-1DDB5AC6-8A38-4BED-8D25-004109B29136Q36983501-659F63F8-963E-4C64-AD61-4A32E2B6B1D4Q37024417-A7A4D870-F0E3-4929-A7CB-07A06866B77BQ37825903-C81F4109-C8EC-4236-A562-FE663F200311Q37880856-67344D3F-A5ED-4A2A-9902-DFF4F73B3F08Q38646050-59EBAF8D-57B5-471A-8541-A1A5D9AE6AE2Q39030028-378E92FE-8362-46CC-A10C-91DA04B99E29Q39470591-5496B9DB-5486-4533-96C1-D4F242690224Q39979455-F6417E94-2E8A-411F-B637-175EEEDFEC6FQ42118645-29B2C98F-7A06-4DD9-AE16-A66F91700270Q46134367-A2FD66B0-3A81-439B-80A6-F6043A2D6425Q46759901-55C44B35-3A53-4963-BEE9-F62823A738CCQ57177843-973F917E-8316-42AC-AD4C-5D71D4206C08
P2860
The PCSK9 gene R46L variant is associated with lower plasma lipid levels and cardiovascular risk in healthy U.K. men.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
The PCSK9 gene R46L variant is ...... ular risk in healthy U.K. men.
@en
The PCSK9 gene R46L variant is ...... ular risk in healthy U.K. men.
@nl
type
label
The PCSK9 gene R46L variant is ...... ular risk in healthy U.K. men.
@en
The PCSK9 gene R46L variant is ...... ular risk in healthy U.K. men.
@nl
prefLabel
The PCSK9 gene R46L variant is ...... ular risk in healthy U.K. men.
@en
The PCSK9 gene R46L variant is ...... ular risk in healthy U.K. men.
@nl
P2093
P356
P1433
P1476
The PCSK9 gene R46L variant is ...... ular risk in healthy U.K. men.
@en
P2093
Andrew H W Neil
Christina Hubbart
Jackie A Cooper
Marileia Scartezini
Ros A Whittall
Steve E Humphries
P304
P356
10.1042/CS20070150
P407
P577
2007-12-01T00:00:00Z